Silvia Tognazzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5391751/publications.pdf

Version: 2024-02-01

33	2,636	218677	395702
papers	citations	26 h-index	33 g-index

33	33	33	5494
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
2	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	2.5	102
3	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
4	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
5	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
6	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
7	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
8	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
9	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
10	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
11	FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	2.9	91
12	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
13	CDKN2AUnclassified Variants in Familial Malignant Melanoma: Combining Functional and Computational Approaches for Their Assessment. Human Mutation, 2014, 35, 828-840.	2.5	17
14	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
15	Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. Breast Cancer Research and Treatment, 2012, 132, 1009-1023.	2.5	56
16	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	2.5	34
17	Contribution of susceptibility gene variants to melanoma risk in families from the Veneto region of Italy. Pigment Cell and Melanoma Research, 2011, 24, 728-730.	3.3	12
18	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	5.0	71

#	Article	IF	Citations
19	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	2.9	68
20	Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival. Haematologica, 2007, 92, 478-485.	3.5	53
21	Factor XIIIA-V34L and Factor XIIIB-H95R Gene Variants: Effects on Survival in Myocardial Infarction Patients. Molecular Medicine, 2007, 13, 112-120.	4.4	32
22	Influence of gene polymorphisms in ulcer healing process after superficial venous surgery. Journal of Vascular Surgery, 2006, 44, 554-562.	1.1	43
23	Prognostic role of factor XIII gene variants in nonhealing venous leg ulcers. Journal of Vascular Surgery, 2006, 44, 815-819.	1.1	45
24	Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention. Journal of the American College of Cardiology, 2006, 48, 2178-2185.	2.8	140
25	Vision Loss after PDT. Ophthalmology, 2006, 113, 157.e1-157.e4.	5.2	7
26	Serum Iron and Matrix Metalloproteinase-9 Variations in Limbs Affected by Chronic Venous Disease and Venous Leg Ulcers. Dermatologic Surgery, 2006, 31, 644-649.	0.8	31
27	The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis. Free Radical Biology and Medicine, 2006, 40, 1869-1873.	2.9	61
28	Serum Iron and Matrix Metalloproteinase-9 Variations in Limbs Affected by Chronic Venous Disease and Venous Leg Ulcers. Dermatologic Surgery, 2005, 31, 644-649.	0.8	42
29	Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. Journal of Vascular Surgery, 2005, 42, 309-314.	1.1	89
30	Factor XIII Contrasts the Effects of Metalloproteinases in Human Dermal Fibroblast Cultured Cells. Vascular and Endovascular Surgery, 2004, 38, 431-438.	0.7	37
31	Factor XIII V34L polymorphism modulates the risk of chronic venous leg ulcer progression and extension. Wound Repair and Regeneration, 2004, 12, 512-517.	3.0	43
32	Prevalence of factor XIII Val34Leu polymorphism in patients affected by spontaneous subconjunctival hemorrhage. American Journal of Ophthalmology, 2004, 138, 481-484.	3.3	14
33	A common mutation in the gene for coagulation factor XIIIâ€A (VAL34Leu): A risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. American Journal of Hematology, 2001, 67, 183-188.	4.1	97